UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 4, 2004
BioMarin Pharmaceutical Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 000-26727 | 68-0397820 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| 371 Bel Marin Keys Boulevard, Suite 210, Novato, California |
94949 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (415) 506-6700
Not Applicable
(Former name or former address, if changed since last report)
Item 7. Financial Statements and Exhibits.
| (a) | Financial Statements of Business Acquired. |
Not Applicable.
| (b) | Pro Forma Financial Information. |
Not Applicable.
| (c) | Exhibits. |
| Exhibit 99.1 | Press Release of BioMarin Pharmaceutical Inc. (the “Company”) dated May 4, 2004. |
Item 12. Results of Operations and Financial Condition.
On May 4, 2004, the Company announced financial results for its first quarter ended March 31, 2004. The Company’s press release issued on May 4, 2004 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BioMarin Pharmaceutical Inc., a Delaware corporation | ||
| (Registrant) | ||
| Date May 4, 2004 |
/s/ Louis Drapeau | |
| Louis Drapeau Chief Financial Officer | ||
EXHIBIT INDEX
| Exhibit No. |
Description | |
| Exhibit 99.1 | Press Release of the Registrant dated May 4, 2004 |